NASDAQ · LXEO
Healthcare · Biotechnology
$3.06
Down-$0.07 (-2.24%)
Updated Oct 30, 2026, 8:31 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LXEO
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
LXEO closed at $3.06 after 21 trading sessions, down 15.47% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $3.16 | $3.375 | $3.05 | $3.06 | 1.05M |
| Oct 28, 2026 | $2.85 | $3.14 | $2.78 | $3.13 | 1.2M |
| Oct 27, 2026 | $2.71 | $2.935 | $2.65 | $2.87 | 2.68M |
| Oct 26, 2026 | $2.80 | $2.825 | $2.675 | $2.70 | 1.16M |
| Oct 23, 2026 | $2.87 | $2.965 | $2.73 | $2.80 | 619.38K |
| Oct 22, 2026 | $2.98 | $3.12 | $2.89 | $2.89 | 492.47K |
| Oct 21, 2026 | $3.03 | $3.09 | $2.97 | $3.00 | 1.08M |
| Oct 20, 2026 | $2.76 | $3.055 | $2.71 | $3.02 | 1.28M |
| Oct 19, 2026 | $2.65 | $2.81 | $2.55 | $2.76 | 1.86M |
| Oct 16, 2026 | $2.75 | $2.84 | $2.63 | $2.64 | 2.51M |
| Oct 15, 2026 | $2.66 | $2.83 | $2.61 | $2.76 | 1.3M |
| Oct 14, 2026 | $2.70 | $2.785 | $2.56 | $2.63 | 1.94M |
| Oct 13, 2026 | $3.09 | $3.09 | $2.74 | $2.74 | 1.59M |
| Oct 12, 2026 | $3.22 | $3.22 | $3.04 | $3.04 | 1.05M |
| Oct 9, 2026 | $3.21 | $3.34 | $3.115 | $3.23 | 961.38K |
| Oct 8, 2026 | $3.27 | $3.28 | $3.1113 | $3.21 | 2.55M |
| Oct 7, 2026 | $3.27 | $3.465 | $3.22 | $3.31 | 1.2M |
| Oct 6, 2026 | $3.43 | $3.43 | $3.17 | $3.30 | 1.54M |
| Oct 5, 2026 | $3.56 | $3.655 | $3.37 | $3.41 | 1.86M |
| Oct 2, 2026 | $3.66 | $3.6885 | $3.495 | $3.53 | 2.59M |
| Oct 1, 2026 | $3.38 | $3.68 | $3.2953 | $3.62 | 2.89M |
The latest Smart Investors Daily articles mentioning LXEO.
Company
Market Activity
Research & News
LXEO research
Filterable reporting and market headlines.
Filters are reflected in the page URL for sharing and back-button support.
3 matching articles.
Yahoo · Oct 25, 2026
Lexeo Therapeutics (NASDAQ:LXEO) outlined upcoming clinical and regulatory milestones for its gene therapy programs in Friedreich’s ataxia cardiomyopathy and PKP2-associated arrhythmogenic cardiomyopathy during the Chardan Healthcare Conference. Chief Financial Officer Lou Tamayo said the clinical-
SeekingAlpha · Oct 24, 2026
2026-10-24. The following slide deck was published by Lexeo Therapeutics, Inc.
Yahoo · Oct 24, 2026
Lexeo Therapeutics (NASDAQ:LXEO) outlined its approach to evaluating LX2020, an investigational AAVrh10-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy, or ACM, ahead of an expected clinical and regulatory update later this quarter. CEO Nolan Townsend said PKP2 ACM is a serious
The latest Smart Investors Daily articles mentioning LXEO.
